Mutations in CEP290 are the most common cause of Leber congenital amaurosis (LCA), a severe inherited retinal degenerative disease for which there is currently no cure. Autosomal recessive CEP290-associated LCA is a good candidate for gene replacement therapy, and cells derived from affected individuals give researchers the ability to study human disease and therapeutic gene correction in vitro. Here we report the development of lentiviral vectors carrying full-length CEP290 for the purpose of correcting the CEP290 disease-specific phenotype in human cells. A lentiviral vector containing CMV-driven human full-length CEP290 was constructed. Following transduction of patient-specific, iPSC-derived, photoreceptor precursor cells, reverse transcriptase-PCR analysis and western blotting revealed vector-derived expression. As CEP290 is important in ciliogenesis, the ability of fibroblast cultures from CEP290-associated LCA patients to form cilia was investigated. In cultures derived from these patients, fewer cells formed cilia compared with unaffected controls. Cilia that were formed were shorter in patient-derived cells than in cells from unaffected individuals. Importantly, lentiviral delivery of CEP290 rescued the ciliogenesis defect. The successful construction and viral transfer of full-length CEP290 brings us closer to the goal of providing gene-and cell-based therapies for patients affected with this common form of LCA.
INTRODUCTION
Leber congenital amaurosis (LCA) is a term used to refer to a group of severe inherited retinal disorders characterized by poor vision within the first year of life, nystagmus, and a non-recordable electroretinogram. 1 LCA is almost always inherited in an autosomal recessive manner and about 30% of LCA patients harbor mutations in the CEP290 gene making it the most common contributor. 2, 3 CEP290 is a centrosomal protein that is localized to the connecting cilium of the photoreceptors 4, 5 and is involved in both ciliogenesis and ciliary trafficking. [6] [7] [8] [9] Patients with CEP290-associated LCA retain some cone nuclei in the central cone-rich foveal region. However, these cone photoreceptors have abnormal inner and outer segments resulting in severe vision loss in most patients. 10, 11 Magnetic resonance imaging studies have demonstrated that the anatomy of CEP290-associated LCA patients' intracranial visual pathways is normal, suggesting that gene-and/or cell-based treatments could restore vision 10 if the therapy could be delivered at an early enough age that the thalamic and cortical centers were still capable of meaningful interpretation of the information being transmitted from the retinal ganglion cells.
Very encouraging in the latter regard is the visual improvement that has been observed in a number of subjects enrolled in clinical trials of adeno-associated virus (AAV)-mediated gene therapy for RPE65-associated LCA. [12] [13] [14] Although it will undoubtedly be possible to devise some type of effective gene transfer approach for the treatment of CEP290-associated LCA, the size of CEP290 precludes the use of the AAV vector system for packaging the fulllength gene. Thus, using lentivirus (which has a larger packaging limit-8-10 versus 4.7 kb) 15 will be advantageous as it can accommodate the full-length CEP290 complementary DNA (cDNA; 7972 nt). Moreover, lentiviral vectors can transduce multiple cell types in the eye, including photoreceptors, 16, 17 which are the retinal cells most affected by CEP290 mutations.
Induced pluripotent stem cell (iPSC)-based technologies are now providing researchers with the ability to model and study human diseases and to evaluate various therapeutic modalities in vitro. Recently, we were able to demonstrate that transplantation of iPSC-derived photoreceptor precursor cells (PRPCs) generated from normal mice restored retinal structure and function in a mouse model of a retinal degenerative disease. 18 We have also used patient-specific iPSC-derived retinal progenitor cells to investigate the pathophysiology of autosomal recessive retinitis pigmentosa caused by mutations in MAK and USH2A. 19, 20 Together, these studies illustrate the utility of iPSC technology for the investigation of pathophysiologic mechanisms involved in inherited retinal diseases and lay the groundwork for the in vitro investigation of gene replacement strategies for treating these disorders.
Here we describe the development of a lentiviral vector expressing full-length human CEP290 and demonstrate its ability to rescue the ciliogenesis defect observed in patient-derived fibroblasts. Furthermore, we report the generation and characterization of iPSCs from mice and humans affected with CEP290-associated LCA and the subsequent differentiation and characterization of photoreceptor precursors. Finally, we demonstrate gene transfer to iPSC-derived PRPCs using this vector.
RESULTS

Full-length human CEP290 is packaged into a lentiviral vector
The CEP290 CDS is too large (~8 kb) to package into the AAV system that was successfully used to treat RPE65-associated LCA. 12, 13, 21 However, lentivirus has a much larger packaging limit (8-10 kb) and is capable of efficient transduction of post-mitotic retinal cells. 15 Therefore, we generated a lentiviral transgene cassette plasmid carrying the CEP290 coding sequence driven by the cytomegalovirus (CMV) promoter (Figure 1a ). When packaged (LV-CMV-hCEP290), the titer was determined to be at least 1 × 10 8 transducing units per milliliter (TU ml -1 ). Using a similar construct with the elongation factor 1 alpha promoter element (1190 versus 585 bp), we were unable to obtain titers higher than 5 × 10 6 TU ml -1 -too low to use in subsequent gene transfer experiments. These findings are in agreement with previously published studies suggesting that for lentiviruses as plasmid size increases, the efficiency of viral packaging decreases. 22 Thus, the full-length wild-type CEP290 coding sequence combined with the CMV promoter appears to be at the size limit for efficient lentiviral packaging.
To demonstrate vector-mediated CEP290 expression, we first transduced a murine cell line, JK1, at increasing multiplicities of infection (MOI). A dose-dependent increase in human CEP290 transcript, as determined by reverse transcriptase (rt)-PCR was observed (Figure 1b) . At 5 days post-transduction, a noticeable drop in cell viability was evident for cultures transduced at an MOI of 5: clumping, morphological changes and death were detected (Figures 1c-f) . As clumping did not occur in cultures transduced with equal amounts of lentiviral vector expressing green fluorescent protein (GFP; Figure 1g ), we hypothesized that overexpression of the CEP290 gene product is cytotoxic. To more accurately evaluate transduction-induced cytotoxicity, cell viability assays were performed (Figures 1h and i) . At 5 days posttransduction, a slight increase in the number of propidium iodidepositive cells was detected in cultures transduced with full-length CEP290 at an MOI of 2, a further statistically significant increase was detected in cultures transduced at an MOI of 5, compared with both untransduced and GFP (MOI of 5) transduced controls (Figure 1j ). No significant increase in cell death was detected in cultures transduced at an MOI of 1. Therefore, subsequent experiments were performed such that the predicted dosage of CEP290 would be below the estimated level of cytotoxicity. Additional control transductions with an identical lentiviral vector expressing unrelated proteins (the multicistronic transcription factors OCT4, SOX2, KLF4 and cMYC) yielded no difference in cell viability at an MOI of 5 compared with untransduced cells (Supplementary Fig. S1 ). Collectively, these data indicate that although we were able to successfully package and express fulllength CEP290 via the lentiviral vector system, overexpression of this gene is cytotoxic. A lentiviral vector expressing human CEP290 transduces iPSCderived photoreceptor precursors To test the ability of the above-described lentiviral gene transfer vector to transduce cell types relevant to the in vivo treatment of CEP290-associated LCA, we first needed to produce patientspecific pluripotent stem cells and use these to derive patientspecific photoreceptor precursors. To begin, dermal fibroblasts isolated from mouse (BXD24/TyJ-Cep290 rd16 /J mouse) 4 and human patients with known disease-causing mutations in CEP290 were targeted for iPSC generation via forced expression of the transcription factors OCT4 (POU5F1), SOX2, KLF4 and cMYC. 23 Approximately 3 weeks after transduction, densely packed colonies of cells with a large nucleus-to-cytoplasm ratio (typical of iPSCs) were identified in both murine (Figure 2a ) and human cultures (Figure 2c ). Following expansion, expression of the pluripotency transcripts NANOG, OCT4, KLF4, LIN28A and DNMT1 was confirmed via rt-PCR (Figures 2b and d) .
To assess the ability of the murine and patient iPSCs to differentiate into tissues specific to each of the three embryonic germ layers, we used teratoma formation assays in immunocompromised mice. At 4 weeks post-injection of murine iPSCs and 8 weeks post-injection of patient-specific iPSCs, teratomas were resected and evaluated histologically. Hemotoxylin and eosin staining of paraffin sections revealed the presence of tissues specific to each of the three embryonic germ layers in murine To produce PRPCs, we used our previously reported step-wise differentiation protocol. To demonstrate vector-mediated CEP290 expression in a disease-relevant cell type, we first transduced iPSC-derived PRPCs from the rd16 mouse with LV-CMV-hCEP290. One week after transduction, we evaluated the presence of vector-derived CEP290 transcript by amplifying a portion of the transcript encoding the deleted in rd16 domain. 25 The deleted in rd16 domain transcript was undetectable in untreated cultures, but was amplified from cells transduced with lentiviral vector (Figure 4a ) demonstrating that CEP290 transgene expression could be accomplished in iPSCderived PRPCs from the rd16 mouse model.
Next we sought to verify lentiviral transduction and wild-type CEP290 expression in iPSC-derived PRPCs from human patients with molecularly confirmed CEP290-associated LCA. Cultures from two patients were transduced at day 90 of the differentiation protocol with LV-CMV-hCEP290. One week following transduction, we evaluated transgene expression via rt-PCR. To differentiate between endogenous and vector-derived transcript, we used primers complimentary to the 3' end of the transcript and the downstream woodchuck post-transcriptional regulatory element that is not present in the endogenous human transcriptome. As with the murine cells, we were able to detect vector-mediated transcript in cultures transduced with LV-CMV-hCEP290 but not in the untransduced control cultures (Figure 4b ). Western blots probed with anti-CEP290 antibody demonstrated that in contrast to untransduced cultures, LV-CMV-hCEP290-transduced PRPCs expressed full-length CEP290 protein (indicated by the presence of a 290 kDa band in both retinal and transduced cell lysates, Figure 4c ). Taken together, these results indicate the feasibility of packaging the large CEP290 transgene into lentiviral vectors and using these vectors to transduce iPSC-derived PRPCs affected with CEP290-associated LCA.
Lentiviral-mediated CEP290 gene addition rescues the ciliogenesis defect in LCA patient-derived dermal fibroblasts CEP290 has a critical role in primary cilium formation and ciliary protein transport. 6, 7, 26 Knockdown experiments in hTERT-RPE cells showed that loss of CEP290 inhibited primary cilium formation. 26 To investigate the ciliogenesis phenotype in LCA patient-specific cells, fibroblasts from four patients with different CEP290 genotypes and an unaffected control individual were cultured under serum-free conditions. Primary cilia and basal bodies were detected via immunocytochemical staining with antibodies targeted against acetylated tubulin (which labels the axonemes of primary cilia) and gamma tubulin (which labels the basal bodies of primary cilia), respectively (Figures 5a-e) . Counting cells from confocal images revealed significantly fewer cells with cilia in LCA patient cultures B054 (34.1 ± 3.0%), B062 (41.6 ± 3.7%) and B620 (50.5 ± 3.6%) when compared with those of an unaffected control individual (WT-64.4 ± 3.2%) (Figure 5f ). Although cells isolated from patient B294 produced fewer cilia (56.7 ± 3.6%) than those isolated from an unaffected individual, this difference did not reach statistical significance. Gamma tubulin-positive basal bodies with no axoneme or stunted/dismorphic axonemes were often identified in patient-specific cells (Figures 5b-e, arrowheads and high magnification inlays).
To determine if CEP290 gene replacement would rescue the disease-specific ciliogenesis phenotype, fibroblast cultures B054, B062 and B620 (the samples with statistically significant ciliogenesis defects), were targeted. Fibroblast cultures were transduced with LV-CMV-hCEP290. As above, the transduced cultures were subjected to serum starvation to induce primary cilium formation. The percentage of ciliated cells in transduced cultures B054 (Figures 6a and b, 34 .1 ± 3.0% and 50.2 ± 3.6%, respectively) and B620 (Figures 6c and d , 50.5 ± 3.6% and 60.7 ± 2.8%, respectively) significantly increased with respect to untransduced cells from the same individuals (Figure 6e , Po 0.01 and P o0.05, respectively). Moreover, the percentage of cells forming cilia in transduced B620 cultures was no longer significantly different from those of the unaffected control. Although, transduction of B062 increased the percentage of cells forming a cilium compared with untransduced B062 controls (48.7 ± 3.4% versus 41.6 ± 3.7%, respectively), the difference was not statistically significant (data not shown).
To further test the efficacy of our gene transfer strategy, the length of the primary cilia, both pre-and post-transduction of lines B054 and B620, was performed (primary cilia were measured from the base, at the basal body, to the tip of the axoneme). As shown in Figure 6f , when cilia lengths were measured, transduced cultures demonstrated significantly longer cilia than their untransduced counterparts. Furthermore, the length of the primary cilia post-transduction was not significantly different from that of the unaffected control. Taken together, these results show that lentiviral-mediated addition of full-length CEP290 is able to rescue the abnormal ciliogenesis phenotype in cells from patients with CEP290-associated LCA.
DISCUSSION
The restoration of vision in patients affected with RPE65-associated LCA via gene replacement therapy 12, 13, 21 was an encouraging milestone for all patients affected with an inherited retinal disease. However, many heritable retinal disorders present two additional challenges: (1) a gene that is too large to package into AAV and (2) a gene product encoding a structural protein that must be expressed in appropriate proportion to other components to function properly. CEP290-associated LCA is such a disease. The CEP290 coding sequence is~8 kb in length, which precludes AAV as a treatment vehicle for the full-length cDNA. In addition, CEP290 is known to physically interact with numerous components within the transition zone of primary cilia. 6, [25] [26] [27] Thus, one may reasonably expect to find-as we did in this study-that a favorable response to CEP290 gene replacement would only occur within a fairly narrow range of gene expression.
We took advantage of the relatively large packaging capacity of lentivirus (8-10 kb), 15 as well as its ability to stably transduce postmitotic retinal cells, to develop a viral vector capable of delivering the full-length CEP290 coding sequence to both patient-specific fibroblasts and iPSC-derived PRPCs. Although we were able to demonstrate vector-mediated expression of CEP290 mRNA in JK1 cells transduced with high concentrations of the vector, these cells exhibited poor viability compared with those transduced with an equal MOI of GFP-expressing vector, suggesting that cell death occurred as a result of CEP290 overexpression. Of note, we have also observed toxicity in mice in which another cilia-associated protein, BBS1, was overexpressed. 28 Our observations agree with previous studies that found photoreceptors to be sensitive to the level of transgene expression. For example, in oxygen-induced retinopathy, overexpression of claudin transmembrane protein results in mislocalization to the cytosolic compartment and neovascularization. 29 Similarly, a fivefold overexpression of the human rhodopsin allele in mice causes photoreceptor degeneration similar to that found in retinitis pigmentosa. 30 Tan et al. 31 also reported a rhodopsin dose-dependent degenerative phenotype in transgenic mice.
Kim et al. 26 reported that hTERT-RPE1 cells failed to form cilia when CEP290 was depleted via small interfering RNA. Furthermore, the rd16 mouse model for CEP290-associated LCA is deficient in primary cilia formation. 7 Thus, we hypothesized that patients with mutations in CEP290 would exhibit a ciliogenesis defect. Indeed, serum-starved fibroblasts from three of four LCA patients formed significantly fewer and shorter primary cilia than those from an unaffected control individual. Importantly, when we treated these cells with LV-CMV-hCEP290, we rescued both the number of cells forming a cilium and the length of the cilia in two of three patients tested, highlighting the fact that different genotypes and genetic backgrounds can result in different levels of cellular pathology. At present, the mechanism by which various disease allele combinations contribute to LCA phenotype(s) is incompletely understood. However, Drivas et al. 7 recently identified functional domains in CEP290 that contribute to membrane and microtubule binding as well as ciliogenesis. One of the alleles carried by patient B062 expresses a truncation mutation in the N-terminal domain. The resulting protein is missing the C-terminal microtubule binding domain (amino acids 1695-1966) 7 and is associated with failure of cilia formation in these cells in vitro. These observations are in agreement with previous results from the rd16 mouse model implicating the requirement of this domain for the formation and maintenance of primary cilia in photoreceptors. 4, 7 Although delivery of full-length CEP290 trended toward restoration of ciliogenesis in this patient, the number of cilia did not increase significantly in treated cells. Perhaps other factors has a role in the pathogenesis of the disease. Indeed, variations in the MKKS and BBS genes have been reported to modify the CEP290 phenotype. 32, 33 Nonetheless, demonstrating rescue of ciliogenesis is an important step in treating these and other patients with CEP290-associated LCA. When culturing PRPCs in vitro, cilia formation is difficult to appreciate. Acetylated tubulin-positive structures can be identified in densely packed neural rosettes, 20 however, tracing these structures back to cell of origin is problematic. Thus, transplantation of corrected PRPCs will be an important future study to determine functional rescue in these cells as full maturation and cilia formation does occur post-transplantation.
Although careful titration of LV-CMV-hCEP290 allowed us to avoid the adverse effects of transgene overexpression in vitro, the manipulation of viral titer alone may not be practical for clinical applications. It will likely be necessary to deliver a very specific amount of CEP290 protein to a specific cell type, such as the photoreceptors. This may be achieved by using the endogenous CEP290 promoter to drive expression of CEP290 cDNA. However, for many genes, like CEP290, the endogenous promoter elements have not yet been identified. Thus, the development of a gene transfer approach in which the transgene is driven under control of its native promoter will require further investigation. An alternative approach that would allow gene transfer-based treatment of a wide variety of retinal degenerative diseases would be to develop a library of synthetic promoters, which would each be capable of a very specific level of transgene expression in a specific retinal cell type.
We predict that the effectiveness of any gene therapy approach for the treatment of CEP290-associated LCA will also be highly dependent upon both the severity of the patients' genotypes and the resultant degree of photoreceptor cell loss at the time treatment is undertaken. In some patients, foveal cones are spared well into adulthood 10, 34 and these cones are sufficient to subserve very useful vision. For others, these cells never seem to function although they can be seen by optical coherence tomography (for example, patient 1). 10 For the latter individuals, delivery of fulllength CEP290 directly to foveal cones may be useful.
Although lentivirus is an effective vector system for packaging cDNAs as large as 8 kb, for genes larger than CEP290 a different vector system will be required. However, it may be possible to adapt the transgene cassette design of this study to other vector systems to allow the efficient construction of constructs that exceed lentivirus and AAV packaging limits with a wide variety of promoters. For example, the herpes simplex virus vector system can accommodate inserts up to~150 kb 35 and can easily transduce dividing and post-mitotic cell types without eliciting an immunological response. 36, 37 Lentivirus integrates into the genomic DNA of transduced cells and thus has the potential for insertional mutagenesis. 38 This is somewhat less of a concern for retinal therapy than it would be for treating cells of other organs or the hematopoietic system because the retina can be readily inspected at microscopic resolution after treatment. If any transduced cells are found to exhibit abnormal growth, they can be destroyed with laser photocoagulation or cryotherapy without harm to the remainder of the eye. Moreover, the continued development of deepsequencing technologies will enable the safety of specific constructs to be assessed by surveying the genome-wide distribution of vector integration. [39] [40] [41] The difficulties associated with large cargo size, the need for precise gene expression and the concerns associated with insertional mutagenesis may all be overcome if genome-editing technologies can be perfected. Transcription activator-like effector nucleases 42, 43 and clustered regularly interspersed short palindromic repeats 44, 45 can be engineered to direct gene correction at specific sites in the genome and may prove useful for in vivo gene correction as well as ex vivo correction of iPSCs [46] [47] [48] before transplantation into diseased tissues.
In summary, we have shown that a lentiviral construct is capable of transducing both mouse and human cells with fulllength CEP290 cDNA and that this transduction results in expression of full-length transcript and functional rescue of the ciliogenesis defect in patient cells. Although this work brings us one step closer to gene-and cell-based treatments of CEP290-associated LCA, strategies for ensuring the proper level of CEP290 expression in treated cells must still be devised before extending this work to human patients.
MATERIALS AND METHODS Patients
All patients provided written, informed consent for this study, which was approved by the Institutional Review Board of the University of Iowa One allele carries the IVS26 mutation, the other allele carries a 2-bp deletion in the coding sequence at amino-acid position 835 (Thr835 del2acAG). Patient B620 carries the IVS26 mutation on one CEP290 allele and an intronic deletion at nucleotide 6277 (6277delG).
Cell culture
We chose to test vector toxicity on the easily propagated, fibroblast-like JK1 cell line because patient fibroblasts are in limited supply. Furthermore, differentiating PRPC cultures exhibit differentiation-induced apoptosis, making cell death assays difficult to perform in a convincing manner. JK1 cells (Cell Biolabs, San Diego, CA, USA) and patient fibroblasts were cultured in complete medium (minimum essential medium α (MEMα; Life Technologies, Grand Island, NY, USA) containing 10% fetal bovine serum (Life Technologies) and 0.2% Primocin (Invivogen, San Diego, CA, USA)).
Lentiviral transduction
JK1 cells (Cell Biolabs) were transduced with lentivirus expressing human CEP290 at a MOIs of 1, 2 and 5 in the presence of polybrene Figure 5 . CEP290 mutations induce a ciliogenesis defect. (a-e) Immunocytochemical analysis of human fibroblast cultures isolated from an unaffected control individual (a) and four patients with CEP290-associated LCA (b-e). Basal bodies were detected with anti-gamma tubulin (red),primary cilia with anti-acetylated tubulin (green; insets), and nuclei with DAPI (blue). Images were collected with 100X high-performance objective. (f) Bars represent the percentage of cells that were positive for acetylated tubulin. Error bars represent s.e. (n ⩾ 6 cultures). **P o0.01, ***Po0.001, ****P o0.0001. WT, unaffected control individual; B054, patient with homozygous IVS26 mutations; B062, patient with IVS26 mutation and Val247del1gT frame shift mutation; B294, patients with IVS26 mutation and Thr833 del2acAG frame shift mutation; B620, patient with IVS26 mutation and 6277delG frame shift mutation. 
Characterization of CEP290 expression
Reverse transcriptase-PCR. Total RNA was isolated and amplified as described above using the forward primer 5'-GCAATGAGCGACTTTTCATCAGAC-3' and the reverse primer 5'-ACAACACCACGGAATTGTCAGTGC-3'. POLR2A transcripts were amplified as an internal control (Supplementary Tables S1 and S2 ).
Immunoblotting. Human retina was obtained from the Iowa Lions Eye Bank (Iowa City, IA, USA) after informed consent of the donors' next of kin and was prepared for immunoblotting as described previously. 19 Differentiated human PRPC cultures from patient B294 at day 60 were transduced with 2 × 10 5 TU LV-CMV-CEP290. Control cultures were left untransduced. One week post-transduction, cells were treated with 0.25% Trypsin-EDTA (Gibco, Life Technologies), homogenized in lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10 mM CaCl 2 , 1% Triton X-100, 0.02% NaN 3 , (Sigma-Aldrich)) and centrifuged. Supernatant protein concentrations were determined via bicinchonic acid according to the manufacturer's instructions (Pierce, Rockford, IL, USA). Fifty micrograms each were iPSC generation Animals used in these studies were cared for in accordance with the Institutional Animal Care and Use Committee (University of Iowa, Iowa City, IA, USA; approval #130815). Murine dermal fibroblasts from the BXD24/TyJCep290 rd16 /J mouse 4 (The Jackson Laboratory, Bar Harbor, ME, USA) and human dermal fibroblasts from LCA patients with mutations in CEP290 were reprogrammed via viral transduction of the transcription factors OCT4, SOX2, KLF4 and cMYC as previously described. 19, 24 Rd16-derived iPSC colonies were cultured in pluripotency medium ((Dulbecco's modified Eagle's medium/F-12; Life Technologies), 15% heat-inactivated fetal bovine serum (Lifeblood Medical Inc., Adelphia, NJ, USA), 0.0008% β-mercaptoethanol (Sigma-Aldrich), 1X nonessential amino acids (Life Technologies), 1 × 10 6 units l -1 leukemia inhibitory factor (Millipore, Billerica, MA, USA), 0.2% Primocin (Invivogen)) on Matrigel-coated plates (BD Biosciences, Franklin Lakes, NJ, USA). Human LCA iPSCs were cultured in mTser1 media on Corning Synthemax-coated plates (Corning, Inc., Corning, NY, USA).
iPSC characterization
Reverse transcriptase-PCR. Total RNA was isolated from passage 10 iPSCs using the RNeasy Mini kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. One hundred nanograms of RNA template was amplified in one-step rt-PCR reactions using the Superscript III One-
Step RT-PCR System (Life Technologies) with primers hybridizing to NANOG, OCT4, KLF4, DNMT1 and LIN82A transcripts from mouse (Supplementary Table S1 ) or human (Supplementary Table S2 ).
Teratoma formation. Severe combined immunodeficiency mice (SCID; The Jackson Laboratories) were used to assess the ability of iPSCs to form teratomas containing tissues of all three germ layers. Approximately 2 × 10 6 cells were resuspended in 100 μl Hank's Buffered Saline Solution (Life Technologies) and injected intramuscularly into the rear limb of SCID hosts. Six to 8 weeks following injection, tumors were resected and analyzed for the presence of tissues of ectodermal, mesodermal and endodermal origin.
Histology. Teratomas were fixed in 10% formalin, embedded in paraffin, sectioned, and counterstained with hemotoxylin and eosin using standard protocols.
Immunocytochemistry. Teratoma sections were de-paraffinized, fixed in 4% paraformaldehyde, and stained with antibodies targeted against alpha fetoprotein (R&D Systems, Minneapolis, MN, USA; 1:100), glial fibrillary acidic protein (Life Technologies; 1:100), and smooth muscle actin (Abcam; 1:100). Slides were coverslipped as described above and imaged on an EVOS fluorescent microscope (Life Technologies).
iPSC differentiation Rd16 and LCA patient-specific iPSCs were cultured on ultra low-binding plates (Corning Life Sciences, Tewksbury, MA, USA) in embryoid body formation medium (Dulbecco's modified Eagle's medium/F-12 (Life Technologies), 10% knockout serum replacement (Life Technologies), 2% B27 supplement (Life technologies), 1% N 2 supplement (Life Technologies), 1% L-glutamine (Life Technologies), 1X nonessential amino acids (Life Technologies), 0.2% Primocin (Invivogen), 1 ng ml -1 Dkk-1 (R&D Systems), 1 ng ml -1 insulin-like growth factor-1 (R&D Systems), 1 ng ml -1 Noggin (R&D Systems) and 0.5 ng ml -1 bFGF (R&D Systems)) for 4-5 days.
Embryoid bodies (200-300 per well) were plated on six-well plates (Corning Life Sciences) coated with collagen (BD Bioscience, San Jose, CA, USA; 25 ug ml -1 ), laminin (Life Technologies; 50 ug ml -1 ) and fibronectin (Sigma-Aldrich; 100 ug ml -1 ) and cultured in differentiation medium one (Dulbecco's modified Eagle's medium/F-12 (Life Technologies), 2% B27 supplement (Life Technologies), 1% N 2 supplement (Life Technologies), 1% L-glutamine (Life Technologies), 1X nonessential amino acids (Life Technologies), 0.2% Primocin (Invivogen), 10 ng ml -1 Dkk-1 (R&D Systems), 10 ng ml -1 insulin-like growth factor-1 (R&D Systems), 10 ng ml -1 Noggin (R&D Systems) and 5 ng ml -1 bFGF (R&D Systems)). Embryoid bodies were differentiated for 10 days followed by 6 days in differentiation medium two ((differentiation media one plus 10 μM DAPT (Calbiochem, Gibbstown, NJ, USA)) and an additional 12 days of culture in differentiation medium three ((differentiation media two plus 2 ng ml -1 acidic fibroblast growth factor (R&D Systems)). Human photoreceptor precursors were cultured an additional 60 days in differentiation medium four (Dulbecco's modified Eagle's medium/F-12 (Life Technologies), 2% B27 supplement (Life Technologies), 1% N 2 supplement (Life Technologies), 1% L-glutamine (Life Technologies), 1X nonessential amino acids (Life Technologies), 0.2% Primocin (Invivogen)).
Differentiation characterization
Reverse transcriptase-PCR. Total RNA was isolated and amplified as described above using primers hybridizing to OTX2, OPSN1SW and ROM1 transcripts (Supplementary Table S3 ).
Immunocytochemistry. iPSC-derived PRPCs from the rd16 mouse model were fixed, stained and imaged as described above with antibodies targeted against Otx2 (R&D Systems; 1:100) and Opsn1sw (EMD Millipore, Billerca, MA, USA; 1:100). Cells from LCA patients were stained with antibodies targeted against OTX2 (EMD Millipore; 1:100) and OPSN1SW (EMD Millipore; 1:100).
Ciliogenesis in patient fibroblast cultures
Fibroblasts from four patients (B054, B062, B294 and B620) and an unaffected control individual were cultured on collagen-coated chamber slides in serum-free conditions (MEMα (Life Technologies), 2% v/v Primocin (Life Technologies)) for 72 h. Cells were fixed in 4% paraformaldehyde and methanol and stained with antibodies targeted against acetylated tubulin (1:200, Sigma-Aldrich) and gamma tubulin (Sigma-Aldrich; 1:1000). Slides were coverslipped with poly(vinyl alcohol)-based mounting medium containing 1,4-diazabicyclo[2.2.2]octane (DABCO) (100 μg ml -1 poly(vinyl alcohol), Sigma-Aldrich; 25% v/v glycerol, Sigma-Aldrich; 0.1M Tris-HCl, pH 8-8.5, 25 μg ml -1 DABCO, Sigma-Aldrich) and 4',6-diamidino-2-phenylindole dihydrochloride) (Sigma-Aldrich; 1:10 000).
Ciliogenesis rescue in patient fibroblast cultures
Fibroblasts from patients B054, B062, B294 and B620 were transduced with lentivirus expressing CEP290 at a MOI of 2 in the presence of polybrene (Sigma-Aldrich) for 6 h in MEMα (Life Technologies) and cultured in complete medium for 6 days. Five thousand transduced cells were passaged into each well of collagen-coated 16-well chamber slides. The following day, cells were cultured in serum-free conditions (MEMα (Life Technologies), 0.2% Primocin (Life Technologies)) for 72 h. Cells were fixed and stained for acetylated tubulin and gamma tubulin as indicated above.
Confocal microscopy analysis of ciliogenesis
Following ciliogenesis and antibody labeling of patient fibroblasts, the slides were coded to eliminate any bias in the experiment. Cells and cilia were imaged and then counted by two individuals, both of whom were masked to the identity of the treatment groups. Cilia were imaged using a Leica DM 2500 SPE confocal microscope (Leica Microsystems, Wetzlar, Germany). Fields of cells were found using 4',6-diamidino-2-phenylindole dihydrochloride followed by imaging acetylated and gamma tubulin channels. Primary cilia were counted as elongated or punctate acetylated tubulin-positive structures localized to nuclei or immediately perinuclear.
Quantification of cilia length. Cilia were imaged via confocal microscopy as described above using a 63X high-performance objective. Cilia were measured using Leica LAS-AF, Version 3.2.0 software (Leica Microsystems). Briefly, images were magnified and cilia (n ⩾ 100) were measured using the scale bar tool specified for the 63X objective. Cilia displaying clear labeling
